The efficacy of Rivastigmine in the management of the behavioral and psychological symptoms of lewy body dementia- a review of literature

Size: px
Start display at page:

Download "The efficacy of Rivastigmine in the management of the behavioral and psychological symptoms of lewy body dementia- a review of literature"

Transcription

1 Review article: The efficacy of Rivastigmine in the management of the behavioral and psychological symptoms of lewy body dementia- a review of literature Dr. Ivan Netto 1, Aditya Iyer 2, Dr. Prathamesh Kamble 3 1 M.D. Consultant Psychiatrist, E-10 Parmar Plaza Clinic, Fatimanagar, Pune India ; 2 Undergraduate student, BJGMC, Pune. 3 Assistant Prof, Physiology, BJGMC, Pune. Corresponding author : Dr Ivan Netto Abstract Dementia with Lewy bodies (DLB) is seen in 20% of the cases of dementia. Behavioral and psychological symptoms of dementia (BPSD) are commonly seen in patients with DLB. BPSD are however difficult to control especially in DLB and this is one of the main reasons leading to the institutionalization of DLB patients. An electronic search was done on PubMed using the key words Rivastigmine AND Lewy Body Dementia AND Behavioral and psychological symptoms of dementia.only studies relating to the use of Rivastigmine for the management of BPSD in DLB were selected.the data of 6 studies were extracted under the following headings author, year of publication, study design, sample size, tools for the assessment of the severity of dementia / BPSD and rivastigmine usage(dose, frequency, duration, side-effects and efficacy). 6 studies reported about the efficacy of Rivastigmine for BPSD in DLB according to consensus criteria. All studies were foreign studies published from the year Two studies received grants. Most were case reports but there was also a randomizeddouble bind-placebo control trial, an open- label- trial and a case series study. Most used the MMSE, for the assessment of the severity of dementia, NPI for the assessment of the control BPSD and the UPDRS for the assessment of Parkinson symptoms. The maximum rivastigmine dosage was 12mg/day given in two divided doses. Gastro-intestinal side effects were the most common side effects. There were no serious life-threatening adverse effects. Rivastigmine was efficacious for the management of BPSD in DLB. The maximum efficacy was for the control of hallucinations. A good response was also seen for the control of agitation, apathy and delusions. Another prominent feature reported was a partial or complete resolution of the sleep/wake cycle and the relief of confusion symptoms. Only one study recorded a dosage- dependent- reversible worsening of the Parkinson symptoms and one a prominent improvement in Parkinson symptoms. There exists evidence for the efficacy of Rivastigmine in the management of BPSD in DLB. These have important implications for patient care, training of mental health professionals and further research. Keywords: Rivastigmine, Lewy body dementia, BPSD Introduction Dementia with Lewy bodies (DLB) is seen in 20% of patients with dementia. The clinical features are cognitive decline, inattention to routine activities, visual hallucinations, Parkinsonism and other neuropsychiatric symptoms. The diagnosis of Lewy body dementia on a clinical level is made by the consensus criteria established by the report of the consortium on the DLB international workshop[1]. Many cases of DLB present with behavioral and psychological symptoms of dementia (BPSD). BPSD is a mixed group of symptoms of agitation, depression and apathy. They are difficult to control and lead to a major source of care giver burden and hence early institutionalization of DLB patients[2,3]. 53

2 Various pharmacotherapies have been used for the control of BPSD in DLB. Neuroleptic medication is known to have adverse side effects like exacerbations of extrapyramidal symptoms and increase mortality[4,5,6,7]. Benzodiazepines although useful in treating anxiety and agitation have been known to lead to falls, injuries and delirium[8]. SSRIs have also been tried however definitive evidence is still lacking[9]. Cholinergic drugs are primarily used for the treatment of cognitive decline in dementia. However there are some reports regarding the use of them for the control of BPSD in patients with DLB[10]. Various cholinergic drugs have been tried but amongst them rivastigmine, a carbamate type of cholinesterase inhibitor, has shown good efficacy. Rivastigmine inhibits both acetylcholinesterase and butyrlcholinesterase enzymes and has predominantly a central action with less peripheral side effects[14]. At present there are no previous reviews regarding the efficacy of Rivastigmine in the management of BPSD in DLB. This review will examine the evidence regarding the efficacy of Rivastigmine in the management of BPSD in DLB. This has important implications for clinical management, training and future research in patients of DLB with BPSD. Methods We did an electronic search in the database PubMed, using a combination of the following search items: Rivastigmine, Lewy body dementia and Behavioral & psychological symptoms of dementia. Only articles from the year 2000 to 2014, related to the use of Rivastigmine, for the management of BPSD in Lewy body dementia (DLB) were selected. Animal studies, postmortem studies and theory based studies were excluded. Studies in languages other than English were also excluded due to the unavailability of translations.data from the selected articles were extracted under the following headings: authors, year of publication, study design, sample size, tools for the assessment of dementia/severity of BPSD and Rivastigmine usage (dose, duration, frequency, side-effects & efficacy). The results obtained were tabulated. Results 6 studies related to the efficacy of Rivastigmine in management of BPSD in DLB were studied. Year of publication All 6 studies were published during the period 2000 to Two were in the year 2000, one in 2001, one in 2005, one in 2007 and one in The earliest was in 2000 the latest study was in the year Location of the study All 6 studies were foreign studies. There were no Indian studies. Funding Out of the 6 studies, 2 received grants[12,15], 2 did not receive[14,16] and two did not mention whether grants were received[11,13]. Study design Out of the 6 studies, one was a randomized-double blindplacebo controlled trial[11], one an open- label- trial[12], one a case series[13]and 3 were case reports[14,15,16]. Sample size There were 120 patients reported in the randomized -double blind- placebo controlled trial[11] and 11 patients in the open label trial[12]. The case series mentioned 8 cases of which case 7 was excluded as it was atypical and treated with haloperidol[13]. There were 3 case reports[14,15,16]. Type of dementia studied All 6 studies evaluated only cases of DLB, using the consensus criteria for clinical diagnosis[11,12,13,14,15,16]. Scales used Various scales were used to measure the severity of dementia, BPSD and the symptoms of Parkinson s disease. The MMSE (Mini-mental status examination) was used to assess the level of cognitive function and the severity of dementia in 5 out of the 6 studies[11,12,13,14,16]. NPI (Neuropsychiatric inventory) was used to assess the severity of BPSD in 4 out of the 6 studies[11,12,13,15]. NPI-4 was used in 2 out of the 6 studies [11,12]. It is a 54

3 subscale (modification) of the NPI and is more specific in to assessment BPSD than the conventional NPI. Only one study employed video polysomnography as a method to document BPSD symptom of a patient[16]. UPDRS (Unified Parkinson disease rating scale) was used for the assessment of concomitant Parkinson s disease in 3 of the 6 studies[11,12,15]. Rivastigmine Used in the dose range of 6mg/day to 12mg/day [11,12,13,14,15,16]. The drug was administered in all the studies as a twice daily dosing regimen. The response to treatment (control of BPSD) at follow up was assessed using the NPI scale and/or the NPI-4 subscale. Side effect profile Most studies reported gastrointestinal side effects like nausea, vomiting and diarrhea [11,12,13]. There were no serious adverse effects reported. Only one study recorded a dosage- dependent- reversible worsening of the Parkinson symptoms [15]. The case series study mentions about the waning off of gastrointestinal side effects due to the development of tolerance [13]. Efficacy of Rivastigmine All the six studies concluded that Rivastigmine was efficacious in the management of BPSD in DLB. The maximal efficacy of Rivastigmine was seen inthe amelioration of hallucinations[11,12,13,14,15]. A good response was also seen for agitation[11,12,15], apathy[11,12] and delusions[11,12,13,15]. Another prominent feature affected in most studies was a partial or complete resolution of the sleep/wake cycle disturbance[13,16] and the relief of confusion symptoms[13,16]. Discussion DLB is a type of dementia with associated Parkinson symptoms. BPSD is commonly seen in patients with DLB. The lack of control of BPSD leads to the early institutionalization of DLB patients. Various pharmacotherapies have been tried but they are associated with adverse effects, elevated mortality and worsening of Parkinson s symptoms usually seen in DLB. The cholinesterase inhibitors have shown great promise in the control of BPSD symptoms. Among them Rivastigmine has been shown to be the most efficacious hence we examined the evidence for the same[10]. This review examined 6 studies reporting about the efficacy of Rivastigmine in management BPSD in patients with DLB. There is evidence from these studies that Rivastigmine is efficacious for the management of BPSD in DLB. The maximum efficacy was for the control of hallucinations[11,12,13,14,15]. A good response was also seen for the control of agitation, apathy and delusions. Another prominent feature reported in most studies was a partial or complete resolution of the sleep/wake cycle disturbance[13,16] and the relief of confusion symptoms[13,16]. Only one study recorded a dosagedependent- reversible worsening of the Parkinson symptoms[15] and one an improvement in Parkinson s symtpoms[12]. This shows that there is evidence for the efficacy of Rivastigmine for the control of BPSD in DLB. It is safe without serious adverse effects, elevated mortality and no increase in Parkinson symptoms. Limitations Studies on Rivastigmine in BPSD in DLB were rare and difficult to locate. There were no recent studies after These all studies were foreign studies and no Indian studies. There could have been some bias in the selection of some studies as there was marked heterogeneity in the studies. Most studies were of lower in the hierarchy of evidence namely case reports. Strength of the study 6 studies were carefully evaluated for the efficacy of Rivastigmine in the treatment of BPSD in Lewy body dementia. A clearer picture emerges regarding the efficacy of rivastigmine for the management of BPSD in DLB. 55

4 Table: Part I Sr no Author Year of pub. Study design Sample size Tool for grading dementia Tool for grading BPSD Dose of Rivastigmin e employed Duration of treatment Side effects GIT/ CNS 1 Mckeith 2000 RDBPCM trial 120 MMSE, CGC- PLUS NPI, NPI-4 6mg BD 23 weeks Nausea, vomiting, diarrhoea. 2 Mckeith 2000 Open label trial 11 MMSE NPI, NPI-4 Mean dose 9.6mg/day (4.8mg BD) 35 weeks Nausea, diarrhoea 3 Maclean 2001 Case series 8 MMSE NPI Mean dose employed is 10mg/day ( 5mg BD) Not mentioned 4/8 cases reported GIT side effects 4 Alwahhabi 5 Clerici 2005 Case report 1 MMSE Not mentioned 4.5mg BD Not mentioned Not mentioned 2007 Case report 1 Not reported NPI 6mg/day 9 months Parkinsonian worsening 6 Terzaghi 2010 Case report 1 MMSE, MRI, SPECT Video-PSG 3mg BD Not mentioned Not mentioned 56

5 Table: Part II BPSD Apathy relief Agitation Hallucination Delusion Sleep/ wake cycle Confusional symptoms Anxiety Other Good control Partial control Partial control Partial control No effect No effect Partial control Nil Good control Partial control Partial control Good control No effect No effect No effect Parkinsonian symptoms improved C1 No effect No effect Good control No effect Partial control Good control No effect Nil C2 No effect No effect Partial control No effect Good control No effect No effect Nil C3 No effect No effect Good control No effect Good control No effect No effect Nil C4 No effect No effect Good control No effect Good control No effect No effect Nil C5 No effect No effect Good control Good control No effect Partial control No effect Nil C6 No effect No effect Partial control No effect Partial control Partial control No effect Nil C7 This case has been excluded from the review as it is an atypical case. C8 No effect No effect Good control Good control Good control No effect No effect Delirium resolved No effect No effect Good control No effect No effect No effect No effect Nil No effect Partial control Partial control Partial control No effect No effect No effect Depression partially controlled No effect No effect No effect No effect Partial control Partial control No effect Nil [ Video- PSG= video polysomnography; Year of Pub.= Year of publication; GIT= Gastrointestinal tract; CNS= Central nervous system; C(1-8)= Cases; RDBPCMT= Randomized double blind placebo controlled multicentric trial ] 57

6 Conclusions 6 studies reported about the efficacy of Rivastigmine for BPSD in DLB. All studied reported only about cases of DLB according to consensus criteria. Most studies were from the year All were foreign studies. Two studies received grants[12,15]. Most were case reports[14,15,16] but there was also a randomized-double bind-placebo control trial[11], an open- label- trial[12] and a case series study[13]. Most used the MMSE, for the assessment of the severity of dementia[11,12,13,14,16], NPI for the assessment of the control BPSD[11,12,13,15] and the UPDRS for the assessment of Parkinson symptoms[11,12,15]. The maximum rivastigmine dosage was 12mg/day given in two divided doses[11]. Gastro-intestinal side effects were the most common side effects. There were no serious lifethreatening adverse effects. Rivastigmine was efficacious for the management of BPSD in DLB. The maximum efficacy was for the control of hallucinations [11,12,13,14,15]. A good response was also seen for the control of agitation, apathy and delusions. Another prominent feature reported in most studies was a partial or complete resolution of the sleep/wake cycle and the relief of confusion symptoms[13,16]. There was a reversible dose dependent worsening of Parkinson s symptoms in one study[15] and in one there was improvement in Parkinson s symptoms[12]. Implications We studied the efficacy of rivastigmine in the management of BPSD in DLB. This has implications for patient care, training of mental health professional and further research. Rivastigmine is a safe and efficacious treatment for the control of BPSD in DLB. Mental health professionals need to be made aware of the management of BPSD in DLB in a safe manner with rivastigmine. Better quality studies are further required to establish stronger evidence for the efficacy of Rivastigmine for BPSD in DLB. References: 1.Mckeith IG, Dickson DW, Lowe J,. Diagnosis and management of dementia with Lewy bodies. Neurology. 2005;65: Beeri MS, Werner P, Davidson M,. The cost of behavioral and psychological symptoms of dementia (BPSD) in community dwelling Alzheimer s disease patients.int J Geriatr Psychiatry. 2002;7: Cohen RF, Swanwick GRJ, O Boyle CA,. Behavior disturbance and other predictors of caregiver s burden in Alzheimer s disease. Int J Geriatr Psychiatry. 1997;12: National Institute for Health and Clinical Excellence (NICE). NICE guidelines for dementia: supporting people with dementia and their carers in health and social care. guidance.nice.org.uk/cg42. 5.Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005; 19;294: Heinz A, Knable MB, Coppola R. Psychomotor slowing, negative symptoms and dopamine receptor availability-an IBZM SPECT study in neuroleptic-treated and drug-free schizophrenic patients. Schizophr Res. 1998;31: Ballard C, Hanney ML, Theodoulou M. The dementia antipsychotic withdrawal trial (DART-AD): long term follow-up of a randomized placebo-controlled trial. Lancet Neurol. 2009;8: McKhann G, Drachman D, Folstein M,. Clinical diagnosis of Alzheimer s type: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer s disease. Neurology. 1984;34:

7 9.Netto I, Mane M. The efficacy of SSRI s in the treatment of the behavioral and psychological symptoms of dementia (BPSD): a review. The Orissa journal of psychiatry. 2012;19: Fischer C, Bozanovic R, Atkins J, Rourke S. Treatment of delusions in dementia with Lewy bodies-response to pharmacotherapy. Dement GeriatrCognDisord. 2007;23: Mckeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand r, Cicin-Sain A, Ferrara R, Spiegel R. Efficacy of Rivastigmine in dementia with Lewy bodies: a randomized, double blind, placebo controlled international study. Lancet. 2000;356: Mckeith I, Grace J, Walker Z, Byrne J, Wilkinson D, Stevens T, Perry E. Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial. International journal of geriatric psychiatry. 2000;15: Maclean L, Collins C, Byrne J. Dementia with Lewy bodies treated with Rivastigmine: effects on cognition, neuropsychiatric symptoms, and sleep. International psychogeriatrics. 2001;vol13(3): Alwahhabi F. Successfully switching acetylcholinesterase inhibitor therapy in probable Lewy body dementia. Journal of psychopharmacology. 2005;19(2): Clerici F, Ratti P, Pomati S, Maggiore L, Elia A, Mariani C. Cholinergic balance in dementia with Lewy bodies: reversible worsening of Parkinsonism at Rivastigmine dosage modulation. Neurol Sci. 2007;28: Terzaghi M, Pacchetti C. Argypnia with nocturnal confusional behaviors in dementia with Lewy Bodies: Immediate efficacy of Rivastigmine. Movement disorders. 2010;25: Date of submission: 10 May 2013 Date of provisional acceptance: 18 May 2013 Date of Final acceptance: 28 June 2014 Date of Publication: 15 July 2014 Source of support: Nil; Conflict of interest: Nil 59 54

Psychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias. Aaron H. Kaufman, MD

Psychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias. Aaron H. Kaufman, MD Psychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias Aaron H. Kaufman, MD Psychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias Aaron H. Kaufman, M.D. Health Sciences

More information

Management of Agitation in Dementia. Kimberly Triplett Ferguson, MS4

Management of Agitation in Dementia. Kimberly Triplett Ferguson, MS4 Management of Agitation in Dementia Kimberly Triplett Ferguson, MS4 Objectives 1. Review recommended evaluation of agitated patients with dementia. 2. Discuss evidence concerning nonpharmacologic management.

More information

DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017.

DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017. DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017. Introduction. Parkinson's disease (PD) has been considered largely as a motor disorder. It has been increasingly recognized that

More information

T he prevalence of Parkinson s disease (PD) is nearly 1% in

T he prevalence of Parkinson s disease (PD) is nearly 1% in 708 PAPER Donepezil for cognitive impairment in Parkinson s disease: a randomised controlled study D Aarsland, K Laake, J P Larsen, C Janvin... See end of article for authors affiliations... Correspondence

More information

Management of the Acutely Agitated Long Term Care Patient

Management of the Acutely Agitated Long Term Care Patient Management of the Acutely Agitated Long Term Care Patient 80 60 Graying of the Population US Population Over Age 65 Millions of Persons 40 20 0 1900 1920 1940 1960 1980 1990 2010 2030 Year Defining Dementia

More information

Ian McKeith MD, F Med Sci, Professor of Old Age Psychiatry, Newcastle University

Ian McKeith MD, F Med Sci, Professor of Old Age Psychiatry, Newcastle University Ian McKeith MD, F Med Sci, Professor of Old Age Psychiatry, Newcastle University Design of trials in DLB and PDD What has been learnt from previous trials in these indications and other dementias? Overview

More information

Parkinsonian Disorders with Dementia

Parkinsonian Disorders with Dementia Parkinsonian Disorders with Dementia George Tadros Consultant in Old Age Liaison Psychiatry, RAID, Heartlands Hospital Professor of Dementia and Liaison Psychiatry, Aston Medical School Aston University

More information

Acetylcholinesterase inhibitors: donepezil, rivastigmine, tacrine or galantamine for non-alzheimer s dementia

Acetylcholinesterase inhibitors: donepezil, rivastigmine, tacrine or galantamine for non-alzheimer s dementia STEER 2002; Vol 2: No.2 Acetylcholinesterase inhibitors: donepezil, rivastigmine, tacrine or galantamine for non-alzheimer s dementia Bunmi Fajemisin Evidence search date: November 2001 www.signpoststeer.org

More information

Behavioral and Psychologic Symptoms in Different Types of Dementia

Behavioral and Psychologic Symptoms in Different Types of Dementia ORIGINAL ARTICLE Behavioral and Psychologic Symptoms in Different Types of Dementia Ming-Jang Chiu,* Ta-Fu Chen, Ping-Keung Yip, Mau-Sun Hua, 1 Li-Yu Tang 2 Background/Purpose: Behavioral and psychologic

More information

Clinical Trial Designs for RCTs focussing on the Treatment of Agitation in people with Alzheimer s disease

Clinical Trial Designs for RCTs focussing on the Treatment of Agitation in people with Alzheimer s disease Clinical Trial Designs for RCTs focussing on the Treatment of Agitation in people with Alzheimer s disease Professor Clive Ballard Dr Byron Creese University of Exeter, UK Guardian guide for 2018: Top

More information

Guidelines for the Management of Behavioural and Psychological Symptoms of Dementia (BPSD) Summary document for Primary Care

Guidelines for the Management of Behavioural and Psychological Symptoms of Dementia (BPSD) Summary document for Primary Care Guidelines for the Management of Behavioural and Psychological Symptoms of Dementia (BPSD) Summary document for Primary Care Guidelines for the Management of Behavioural and Psychological Symptoms of Dementia

More information

Antipsychotic Medications

Antipsychotic Medications TRAIL: Team Review of EVIDENCE REVIEW & RECOMMENDATIONS FOR LTC Behavioural and psychological symptoms of dementia (BPSD) refer to the non-cognitive symptoms of disturbed perception, thought content, mood

More information

Behavioral and psychological symptoms of dementia characteristic of mild Alzheimer patients

Behavioral and psychological symptoms of dementia characteristic of mild Alzheimer patients Blackwell Science, LtdOxford, UKPCNPsychiatry and Clinical Neurosciences1323-13162005 Blackwell Publishing Pty Ltd593274279Original ArticleDementia and mild AlzheimersJ. Shimabukuro et al. Psychiatry and

More information

A prospective study of dementia with Lewy bodies

A prospective study of dementia with Lewy bodies Age and Ageing 998; 27: 6-66 998, British Geriatrics Society A prospective study of dementia with Lewy bodies CLIVE G. BALLARD, JOHN O'BRIEN, KATH LOWERX GARETH A. AYRE, RICHARD HARRISON, ROBERT PERRY,

More information

Delirium. Approach. Symptom Update Masterclass:

Delirium. Approach. Symptom Update Masterclass: Symptom Update Masterclass: Delirium Jason Boland Senior Clinical Lecturer and Honorary Consultant in Palliative Medicine Wolfson Centre for Palliative Care Research Hull York Medical School University

More information

Psychosis and Agitation in Dementia

Psychosis and Agitation in Dementia Psychosis and Agitation in Dementia Dilip V. Jeste, MD Estelle & Edgar Levi Chair in Aging, Director, Stein Institute for Research on Aging, Distinguished Professor of Psychiatry & Neurosciences, University

More information

Dementia Diagnosis Guidelines Primary Care

Dementia Diagnosis Guidelines Primary Care Dementia Diagnosis Guidelines Primary Care Dementia Diagnosis Primary Care Guidelines Introduction Dementia is a long term condition, which primarily affects people over the age of 65 (late on-set dementia)

More information

The place for treatments of associated neuropsychiatric and other symptoms

The place for treatments of associated neuropsychiatric and other symptoms The place for treatments of associated neuropsychiatric and other symptoms Luca Pani dg@aifa.gov.it London, 25 th November 2014 Workshop on Alzheimer s Disease European Medicines Agency London, UK Public

More information

The Spectrum of Lewy Body Disease: Dementia with Lewy Bodies and Parkinson's Disease Dementia

The Spectrum of Lewy Body Disease: Dementia with Lewy Bodies and Parkinson's Disease Dementia Disclosures Research support, Parkinson Society Canada, Canadian Institutes of Health Research, Ministry of Economic Development and Innovation, Teva Novartis clinical trial, Principal Investigator CME

More information

NeuroPharmac Journal ISSN: Alzheimer s Disease: Pharmacotherapy of noncognitive symptoms Aslam Pathan; Abdulrahman M.

NeuroPharmac Journal ISSN: Alzheimer s Disease: Pharmacotherapy of noncognitive symptoms Aslam Pathan; Abdulrahman M. ISSNISSN ISSN: 2456-3927 NeuroPharmac Journal Alzheimer s Disease: Pharmacotherapy of noncognitive symptoms Aslam Pathan; Abdulrahman M. Alshahrani www. neuropharmac.com Jan-April 2018, Volume 3, Issue

More information

Antipsychotic use in dementia: a systematic review of benefits and risks from metaanalyses

Antipsychotic use in dementia: a systematic review of benefits and risks from metaanalyses 658463TAJ0010.1177/2040622316658463Therapeutic Advances in Chronic DiseaseRR Tampi, DJ Tampi research-article2016 Therapeutic Advances in Chronic Disease Original Research Antipsychotic use in dementia:

More information

Screening and Management of Behavioral and Psychiatric Symptoms Associated with Dementia

Screening and Management of Behavioral and Psychiatric Symptoms Associated with Dementia Screening and Management of Behavioral and Psychiatric Symptoms Associated with Dementia Measure Description Percentage of patients with dementia for whom there was a documented screening* for behavioral

More information

Cognitive enhancers PINCH ME. Anticholinergic burden BPSD. Agitation, Aggression and antipsychotics

Cognitive enhancers PINCH ME. Anticholinergic burden BPSD. Agitation, Aggression and antipsychotics Cognitive enhancers PINCH ME Anticholinergic burden BPSD Agitation, Aggression and antipsychotics 2 types Cholinesterase inhibitors licensed for mild to moderate AD Donepezil Galantamine Rivastigmine also

More information

Literature Scan: Alzheimer s Drugs

Literature Scan: Alzheimer s Drugs Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

11/11/2016. Disclosures. Natural history of BPSD. Objectives. Assessment of BPSD. Behavioral Management of Persons with Alzheimer s Disease

11/11/2016. Disclosures. Natural history of BPSD. Objectives. Assessment of BPSD. Behavioral Management of Persons with Alzheimer s Disease Disclosures Behavioral Management of Persons with Alzheimer s Disease Wisconsin Association of Medical Directors November 17, 2016 Art Walaszek, M.D. Professor of Psychiatry UW School of Medicine & Public

More information

An Evaluation of a Training Program in Restraint-Free Care for Individuals with Dementia Christina Garrison-Diehn, Clair Rummel, & Jane E.

An Evaluation of a Training Program in Restraint-Free Care for Individuals with Dementia Christina Garrison-Diehn, Clair Rummel, & Jane E. An Evaluation of a Training Program in Restraint-Free Care for Individuals with Dementia Christina Garrison-Diehn, Clair Rummel, & Jane E. Fisher Background Disease. (Xu, Kochanek & Tejada-Vera, 2009)

More information

Behavioural Problems and Patterns of Psychopharmacological Treatment given in Elderly Patients with Dementia

Behavioural Problems and Patterns of Psychopharmacological Treatment given in Elderly Patients with Dementia The International Journal of Indian Psychology ISSN 2348-5396 (e) ISSN: 2349-3429 (p) Volume 6, Issue 4, DIP: 18.01.090/20180604 DOI: 10.25215/0604.090 http://www.ijip.in October-December, 2018 Research

More information

ABSTRACT INTRODUCTION

ABSTRACT INTRODUCTION Neurol Ther (2018) 7:333 340 https://doi.org/10.1007/s40120-018-0109-9 ORIGINAL RESEARCH Decreased Behavioral Abnormalities After Treatment with Combined Donepezil and Yokukansankachimpihange in Alzheimer

More information

Cholinesterase inhibitors for Alzheimer s disease (Review)

Cholinesterase inhibitors for Alzheimer s disease (Review) Birks J This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2008, Issue 3 http://www.thecochranelibrary.com 1 T A B L E O

More information

DRUG THERAPY CHOICES FOR THE DEMENTED PATIENT Past, Present and Future

DRUG THERAPY CHOICES FOR THE DEMENTED PATIENT Past, Present and Future DRUG THERAPY CHOICES FOR THE DEMENTED PATIENT Past, Present and Future Daniel S. Sitar Professor Emeritus University of Manitoba Email: Daniel.Sitar@umanitoba.ca March 6, 2018 INTRODUCTION EPIDEMIOLOGY

More information

Dementia and Delirium

Dementia and Delirium Dementia and Delirium LPT Gondar Mental Health Group www.le.ac.uk Dementia and Delirium WTINP Chapter 4.6 Introduction - areas to be covered Delirium Definition and causes Clinical features Management

More information

IT IS WELL known that individuals with dementia. Classifying eating-related problems among institutionalized people with dementia.

IT IS WELL known that individuals with dementia. Classifying eating-related problems among institutionalized people with dementia. doi:10.1111/pcn.12375 Regular Article Classifying eating-related problems among institutionalized people with dementia Shunichiro Shinagawa, MD, PhD, 1 * Kazuki Honda, MD, PhD, 2 Tetsuo Kashibayashi, MD,

More information

GERIATRIC MENTAL HEALTH AND MEDICATION TREATMENT

GERIATRIC MENTAL HEALTH AND MEDICATION TREATMENT Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences GERIATRIC MENTAL HEALTH AND MEDICATION TREATMENT RUTH KOHEN ASSOCIATE PROFESSOR UW DEPARTMENT OF PSYCHIATRY 5-4-2017

More information

Comparison of cognitive decline between dementia with Lewy bodies and Alzheimer s disease: a cohort study

Comparison of cognitive decline between dementia with Lewy bodies and Alzheimer s disease: a cohort study Open Access To cite: Walker Z, McKeith I, Rodda J, et al. Comparison of cognitive decline between dementia with Lewy bodies and Alzheimer s disease: a cohort study. BMJ Open 2012;2:e000380. doi:10.1136/

More information

NKR 55 demens og medicin PICO 2 seponering af antipsykotisk medicin versus forsat behandling Review information

NKR 55 demens og medicin PICO 2 seponering af antipsykotisk medicin versus forsat behandling Review information NKR 55 demens og medicin PICO 2 seponering af antipsykotisk medicin versus forsat behandling Review information Authors Sundhedsstyrelsen 1 1 [Empty affiliation] Citation example: S. NKR 55 demens og medicin

More information

Diagnosis and Treatment of Alzhiemer s Disease

Diagnosis and Treatment of Alzhiemer s Disease Diagnosis and Treatment of Alzhiemer s Disease Roy Yaari, MD, MAS Director, Memory Disorders Clinic, Banner Alzheimer s Institute 602-839-6900 Outline Introduction Alzheimer s disease (AD)Guidelines -revised

More information

Predicting Lewy Body Pathology in a Community-Based Sample With Clinical Diagnosis of Alzheimer s Disease

Predicting Lewy Body Pathology in a Community-Based Sample With Clinical Diagnosis of Alzheimer s Disease Predicting Lewy Body Pathology in a Community-Based Sample With Clinical Diagnosis of Alzheimer s Disease Debby Tsuang, MD, MSc, Kate Simpson, MPH, Eric B. Larson, MD, MPH, Elaine Peskind, MD, Walter Kukull,

More information

ORIGINAL CONTRIBUTION. Attention and Fluctuating Attention in Patients With Dementia With Lewy Bodies and Alzheimer Disease

ORIGINAL CONTRIBUTION. Attention and Fluctuating Attention in Patients With Dementia With Lewy Bodies and Alzheimer Disease ORIGINAL CONTRIBUTION Attention and Fluctuating Attention in Patients With Dementia With Lewy Bodies and Alzheimer Disease Clive Ballard, MRCPsych, MD; John O Brien, MRCPsych, DM; Alistair Gray, BSc; Franchesca

More information

Dementia is a common neuropsychiatric disorder characterized by progressive impairment of

Dementia is a common neuropsychiatric disorder characterized by progressive impairment of Focused Issue of This Month Diagnosis and Treatment for Behavioral and Psychological Symptoms of Dementia Byoung Hoon Oh, MD Department of Psychiatry, Yonsei University College of Medicine E - mail : drobh@yuhs.ac

More information

CME Geriatric medicine

CME Geriatric medicine CME GERIATRIC MEDICINE Clinical Medicine 2011, Vol 11, No 1: 67 71 CME Geriatric medicine Edited by John Young, professor of elderly care medicine, Academic Unit of Elderly Care and Rehabilitation, Bradford

More information

Sponsor Novartis. Generic Drug Name. NA (not existing yet) Therapeutic Area of Trial Parkinson s Disease L-dopa induced dyskinesia

Sponsor Novartis. Generic Drug Name. NA (not existing yet) Therapeutic Area of Trial Parkinson s Disease L-dopa induced dyskinesia Page 1 Sponsor Novartis Generic Drug Name NA (not existing yet) Therapeutic Area of Trial Parkinson s Disease L-dopa induced dyskinesia Approved Indication Investigational. Study Number CA2206 Title A

More information

SYNOPSIS. Risperidone-R064766: Clinical Study Report RIS-AUS-5 (FOR NATIONAL AUTHORITY USE ONLY)

SYNOPSIS. Risperidone-R064766: Clinical Study Report RIS-AUS-5 (FOR NATIONAL AUTHORITY USE ONLY) SYNOPSIS Protocol No.: RIS-AUS-5 Psychosis in Alzheimer s disease (PAD) analysis Title of Study: Risperidone in the treatment of behavioral and psychological symptoms in dementia: a multicenter, double-blind,

More information

Disclosure. Speaker Bureaus. Grant Support. Pfizer Forest Norvartis. Pan American Health Organization/WHO NIA HRSA

Disclosure. Speaker Bureaus. Grant Support. Pfizer Forest Norvartis. Pan American Health Organization/WHO NIA HRSA Disclosure Speaker Bureaus Pfizer Forest Norvartis Grant Support Pan American Health Organization/WHO NIA HRSA How Common is Psychosis in Alzheimer s Disease? Review of 55 studies 41% of those with Alzheimer

More information

Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer s disease (amended)

Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer s disease (amended) Issue date: November 2006 (amended September 2007) Review date: September 2009 Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer s disease (amended) Includes a

More information

LTC Research Influencing Practice

LTC Research Influencing Practice LTC Research Influencing Practice David A. Nace, MD, MPH Division of Geriatric Medicine naceda@upmc.edu PGS Clinical Update April 6, 2017 Conflicts of Interest Dr. Nace does not have any current conflicts

More information

Optimal Management of Challenging Behaviours in Dementia: An Update on Pharmacologic and Non-Pharmacologic Approaches

Optimal Management of Challenging Behaviours in Dementia: An Update on Pharmacologic and Non-Pharmacologic Approaches Optimal Management of Challenging Behaviours in Dementia: An Update on Pharmacologic and Non-Pharmacologic Approaches Andrea Iaboni, MD, DPhil, FRCPC Toronto Rehab Institute, UHN Learning objectives Recognize

More information

Psychiatric Morbidity in Dementia Patients in a Neurology-Based Memory Clinic

Psychiatric Morbidity in Dementia Patients in a Neurology-Based Memory Clinic Original Articles 179 Psychiatric Morbidity in Dementia Patients in a Neurology-Based Memory Clinic Ching-Sen Shih 1, Sui-Hing Yan 2, Ying-Hoo Ho 1, Yuh-Te Lin 1, Jie-Yuan Li 1, and Yuk-Keung Lo 1 Abstract-

More information

Delirium. Dr. Lesley Wiesenfeld. Deputy Psychiatrist in Chief, Mount Sinai Hospital. Dr. Carole Cohen

Delirium. Dr. Lesley Wiesenfeld. Deputy Psychiatrist in Chief, Mount Sinai Hospital. Dr. Carole Cohen Delirium Dr. Lesley Wiesenfeld Deputy Psychiatrist in Chief, Mount Sinai Hospital Dr. Carole Cohen Department of Psychiatry, University of Toronto and Sunnybrook Health Sciences Centre Case Study Mrs B

More information

SYNOPSIS. Risperidone-R064766: Clinical Study Report RIS-INT-24 (FOR NATIONAL AUTHORITY USE ONLY)

SYNOPSIS. Risperidone-R064766: Clinical Study Report RIS-INT-24 (FOR NATIONAL AUTHORITY USE ONLY) SYNOPSIS Protocol No.: RIS-INT-24 Psychosis in Alzheimer s disease (PAD) analysis Title of Study: Risperidone in the treatment of behavioral disturbances in demented patients: an international, multicenter,

More information

Known as both a thief and murderer,

Known as both a thief and murderer, &A Dementia Drugs: When Should They Be Stopped? Ron Keren, MD, FRCPC As presented at the University of Toronto s Primary Care Conference, Toronto, Ontario (May 25) Known as both a thief and murderer, Alzheimer

More information

The course of neuropsychiatric symptoms in dementia. Part II: relationships among behavioural sub-syndromes and the influence of clinical variables

The course of neuropsychiatric symptoms in dementia. Part II: relationships among behavioural sub-syndromes and the influence of clinical variables INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY Int J Geriatr Psychiatry 2005; 20: 531 536. Published online in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/gps.1317 The course of neuropsychiatric

More information

C holinomimetic drugs constitute the first line of treatment

C holinomimetic drugs constitute the first line of treatment 310 PAPER Cholinesterase inhibitor treatment alters the natural history of Alzheimer s disease O L Lopez, J T Becker, S Wisniewski, J Saxton, D I Kaufer, S T DeKosky... See end of article for authors affiliations...

More information

PDFlib PLOP: PDF Linearization, Optimization, Protection. Page inserted by evaluation version

PDFlib PLOP: PDF Linearization, Optimization, Protection. Page inserted by evaluation version PDFlib PLOP: PDF Linearization, Optimization, Protection Page inserted by evaluation version www.pdflib.com sales@pdflib.com doi:10.1111/j.1479-8301.2007.00215.x PSYCHOGERIATRICS 2008; 8: 32 37 REVIEW

More information

Worldwide, over 40 million people have. Pimavanserin in Alzheimer s Disease Psychosis: Efficacy in Patients with More Pronounced Psychotic Symptoms

Worldwide, over 40 million people have. Pimavanserin in Alzheimer s Disease Psychosis: Efficacy in Patients with More Pronounced Psychotic Symptoms The Journal of Prevention of Alzheimer s Disease - JPAD Volume 6, Number 1, 2019 Original Research The Author(s) Pimavanserin in Alzheimer s Disease Psychosis: Efficacy in Patients with More Pronounced

More information

Coordinating Care Between Neurology and Psychiatry to Improve the Diagnosis and Treatment of Parkinson s Disease Psychosis

Coordinating Care Between Neurology and Psychiatry to Improve the Diagnosis and Treatment of Parkinson s Disease Psychosis Coordinating Care Between Neurology and Psychiatry to Improve the Diagnosis and Treatment of Parkinson s Disease Psychosis Jeff Gelblum, MD Senior Attending Neurologist Mt. Sinai Medical Center Miami,

More information

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process Quality ID #283: Dementia Associated Behavioral and Psychiatric Symptoms Screening and Management National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY

More information

Behavioral and Psychological Symptoms of dementia (BPSD)

Behavioral and Psychological Symptoms of dementia (BPSD) Behavioral and Psychological Symptoms of dementia (BPSD) Chris Collins - Old Age Psychiatrist, Christchurch chris.collins@cdhb.health.nz Approaching BPSD: the right mindset Assessment Non-drug management

More information

Primary Care Prescribing Protocol to Support the Diagnosis and Management of People with Dementia

Primary Care Prescribing Protocol to Support the Diagnosis and Management of People with Dementia Primary Care Prescribing Protocol to Support the Diagnosis and Management of People with Dementia This prescribing guideline provides the necessary information and guidance to support clinicians in the

More information

Non-motor symptoms as a marker of. Michael Samuel

Non-motor symptoms as a marker of. Michael Samuel Non-motor symptoms as a marker of progression in Parkinson s s disease Michael Samuel London, UK 1 Definitions and their problems Non-motor symptoms as a marker of progression Non-motor symptoms (NMS)

More information

ANTIPSYCHOTICS IN LONG TERM CARE: Are We Doing More Harm than Good?

ANTIPSYCHOTICS IN LONG TERM CARE: Are We Doing More Harm than Good? ANTIPSYCHOTICS IN LONG TERM CARE: Are We Doing More Harm than Good? STEPHANIE M. OZALAS, PHARMD, BCPS, BCGP VA MARYLAND HEALTH CARE SYSTEM BALTIMORE, MD DISCLOSURES Off-label use of medications will be

More information

Alzheimer s Disease. Pathophysiology: Alzheimer s disease (AD) is a progressive dementia affecting cognition, behavior,

Alzheimer s Disease. Pathophysiology: Alzheimer s disease (AD) is a progressive dementia affecting cognition, behavior, 2 Alzheimer s Disease Alzheimer s disease (AD) is a progressive dementia affecting cognition, behavior, and functional status with no known cause or cure. Patients eventually lose cognitive, analytical,

More information

MOVEMENT DISORDERS AND DEMENTIA

MOVEMENT DISORDERS AND DEMENTIA MOVEMENT DISORDERS AND DEMENTIA FOCUS ON DEMENTIA WITH LEWY BODIES MADHAVI THOMAS MD NORTH TEXAS MOVEMENT DISORDERS INSTITUTE, INC DEMENTIA de men tia dəˈmen(t)sh(ē)ə/ nounmedicine noun: dementia a chronic

More information

Visual hallucinations in Alzheimer s disease is significantly associated with clinical diagnostic features of dementia with Lewy bodies

Visual hallucinations in Alzheimer s disease is significantly associated with clinical diagnostic features of dementia with Lewy bodies RESEARCH ARTICLE Visual hallucinations in Alzheimer s disease is significantly associated with clinical diagnostic features of dementia with Lewy bodies Pai-Yi Chiu 1, Min-Hsien Hsu 1, Chein-Wei Wang 2,

More information

Dementia. Aetiology, pathophysiology and the role of neuropsychological testing. Dr Sheng Ling Low Geriatrician

Dementia. Aetiology, pathophysiology and the role of neuropsychological testing. Dr Sheng Ling Low Geriatrician Dementia Aetiology, pathophysiology and the role of neuropsychological testing Dr Sheng Ling Low Geriatrician Topics to cover Why is dementia important What is dementia Differentiate between dementia,

More information

Relapse Risk after Discontinuation of Risperidone in Alzheimer s Disease

Relapse Risk after Discontinuation of Risperidone in Alzheimer s Disease original article Relapse Risk after Discontinuation of Risperidone in Alzheimer s Disease D.P. Devanand, M.D., Jacobo Mintzer, M.D., M.B.A., Susan K. Schultz, M.D., Howard F. Andrews, Ph.D., David L. Sultzer,

More information

Appendix N: Research recommendations

Appendix N: Research recommendations Appendix N: recommendations N.1 First-line treatment of motor symptoms recommendation 1 Interventions What is the effectiveness of initial levodopa monotherapy versus initial levodopa-dopamine agonist

More information

LU:research Institutional Repository of Lund University

LU:research Institutional Repository of Lund University LU:research Institutional Repository of Lund University This is an author produced version of a paper published in International journal of geriatric psychiatry. This paper has been peer-reviewed but does

More information

Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer s disease: A meta-analysis

Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer s disease: A meta-analysis ORIGINAL RESEARCH Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer s disease: A meta-analysis Noll Campbell 1 Amir Ayub 2 Malaz A Boustani 2 Chris Fox 3 Martin

More information

Lewy Body Disease. Dementia Education for the First Responder July 27, 2017

Lewy Body Disease. Dementia Education for the First Responder July 27, 2017 Lewy Body Disease Dementia Education for the First Responder July 27, 2017 Dylan Wint, M.D. NV Energy Chair for Brain Health Education Cleveland Clinic Lou Ruvo Center for Brain Health OUTLINE Lewy body

More information

CHAPTER 3.2 RIVASTIGMINE PHARMACOTHERAPY AND CLINICAL PHARMACOLOGY

CHAPTER 3.2 RIVASTIGMINE PHARMACOTHERAPY AND CLINICAL PHARMACOLOGY CHAPTER 3.2 RIVASTIGMINE PHARMACOTHERAPY AND CLINICAL PHARMACOLOGY 71 72 CHAPTER 3.2.1 Discontinuation of rivastigmine in routine clinical practice S.V. Frankfort, B.A. Appels, A. de Boer, C.R. Tulner,

More information

DELIRIUM IN ICU: Prevention and Management. Milind Baldi

DELIRIUM IN ICU: Prevention and Management. Milind Baldi DELIRIUM IN ICU: Prevention and Management Milind Baldi Contents Introduction Risk factors Assessment Prevention Management Introduction Delirium is a syndrome characterized by acute cerebral dysfunction

More information

Characteristics of Visual Hallucinations in Parkinson Disease Dementia and Dementia With Lewy Bodies

Characteristics of Visual Hallucinations in Parkinson Disease Dementia and Dementia With Lewy Bodies Characteristics of Visual Hallucinations in Parkinson Disease Dementia and Dementia With Lewy Bodies Urs P. Mosimann, M.D., Elise N. Rowan Ph.D., Cassie E. Partington, M.Phil., Daniel Collerton M.Sc.,

More information

GALANTAMINE. THERAPEUTICS Brands Razadyne Razadyne ER see index for additional brand names

GALANTAMINE. THERAPEUTICS Brands Razadyne Razadyne ER see index for additional brand names GALANTAMINE THERAPEUTICS Brands Razadyne Razadyne ER see index for additional brand names Generic? Yes Class Neuroscience-based Nomenclature: acetylcholine multi-modal; enzyme inhibitor; receptor PAM (ACh-MM)

More information

Pharmacological Treatments for Neuropsychiatric Symptoms in Dementia 3/22/2018

Pharmacological Treatments for Neuropsychiatric Symptoms in Dementia 3/22/2018 Pharmacological Treatments for Neuropsychiatric Symptoms in Dementia 3/22/2018 Mary Ellen Quiceno, MD, FAAN Associate Professor of Neurology UNTHSC Center for Geriatrics 855 Montgomery Street, PCC 4, Ft.

More information

Worldwide, over 40 million people have. Pimavanserin in Alzheimer s Disease Psychosis: Efficacy in Patients with More Pronounced Psychotic Symptoms

Worldwide, over 40 million people have. Pimavanserin in Alzheimer s Disease Psychosis: Efficacy in Patients with More Pronounced Psychotic Symptoms The Journal of Prevention of Alzheimer s Disease - JPAD Volume 6, Number 1, 2019 Original Research The Author(s) Pimavanserin in Alzheimer s Disease Psychosis: Efficacy in Patients with More Pronounced

More information

Delirium. Assessment and Management

Delirium. Assessment and Management Delirium Assessment and Management Goals and Objectives Participants will: 1. be able to recognize and diagnose the syndrome of delirium. 2. understand the causes of delirium. 3. become knowledgeable about

More information

The most common cause of dementia in the elderly is. Cholinesterase Inhibitors in the Treatment of Dementia REVIEW ARTICLE. Jay M.

The most common cause of dementia in the elderly is. Cholinesterase Inhibitors in the Treatment of Dementia REVIEW ARTICLE. Jay M. Cholinesterase Inhibitors in the Treatment of Dementia Jay M. Ellis, DO Dementia associated with probable Alzheimer s disease (AD) is one of the most common types of dementia. Patients with AD often have

More information

CHAPTER 5 NEUROPSYCHOLOGICAL PROFILE OF ALZHEIMER S DISEASE

CHAPTER 5 NEUROPSYCHOLOGICAL PROFILE OF ALZHEIMER S DISEASE CHAPTER 5 NEUROPSYCHOLOGICAL PROFILE OF ALZHEIMER S DISEASE 5.1 GENERAL BACKGROUND Neuropsychological assessment plays a crucial role in the assessment of cognitive decline in older age. In India, there

More information

AGED SPECIFIC ASSESSMENT TOOLS. Anna Ciotta Senior Clinical Neuropsychologist Peninsula Mental Health Services

AGED SPECIFIC ASSESSMENT TOOLS. Anna Ciotta Senior Clinical Neuropsychologist Peninsula Mental Health Services AGED SPECIFIC ASSESSMENT TOOLS Anna Ciotta Senior Clinical Neuropsychologist Peninsula Mental Health Services Issues in assessing the Elderly Association between biological, psychological, social and cultural

More information

Treatment of behavioral and psychological symptoms of dementia: a systematic review

Treatment of behavioral and psychological symptoms of dementia: a systematic review Psychiatr. Pol. 2016; 50(4): 679 715 PL ISSN 0033-2674 (PRINT), ISSN 2391-5854 (ONLINE) www.psychiatriapolska.pl DOI: http://dx.doi.org/10.12740/pp/64477 Treatment of behavioral and psychological symptoms

More information

Introduction, use of imaging and current guidelines. John O Brien Professor of Old Age Psychiatry University of Cambridge

Introduction, use of imaging and current guidelines. John O Brien Professor of Old Age Psychiatry University of Cambridge Introduction, use of imaging and current guidelines John O Brien Professor of Old Age Psychiatry University of Cambridge Why do we undertake brain imaging in AD and other dementias? Exclude other causes

More information

ORIGINAL CONTRIBUTION. Response of Patients With Alzheimer Disease to Rivastigmine Treatment Is Predicted by the Rate of Disease Progression

ORIGINAL CONTRIBUTION. Response of Patients With Alzheimer Disease to Rivastigmine Treatment Is Predicted by the Rate of Disease Progression ORIGINAL CONTRIBUTION Response of Patients With Alzheimer Disease to Rivastigmine Treatment Is Predicted by the Rate of Disease Progression Martin R. Farlow, MD; Ann Hake, MD; John Messina, PharmD; Richard

More information

Multi-morbidity in Dementia: A 21st Century Challenge. Sube Banerjee. Professor of Dementia Brighton and Sussex Medical School

Multi-morbidity in Dementia: A 21st Century Challenge. Sube Banerjee. Professor of Dementia Brighton and Sussex Medical School Multi-morbidity in Dementia: A 21st Century Challenge Sube Banerjee Professor of Dementia Brighton and Sussex Medical School Most people of any age with any long term condition have multiple conditions

More information

How to Diagnose Early (Prodromal) Lewy Body Dementia. Ian McKeith MD, FRCPsych, F Med Sci.

How to Diagnose Early (Prodromal) Lewy Body Dementia. Ian McKeith MD, FRCPsych, F Med Sci. How to Diagnose Early (Prodromal) Lewy Body Dementia Ian McKeith MD, FRCPsych, F Med Sci. Parkinson s Disease Lewy Body Disease Time PD Dementia Lewy Body Dementias Dementia with Lewy Bodies (DLB) Diagnostic

More information

Dementia NICE Guidelines Update. Key points for primary care - NICE guideline (June 2018 update ) 26 September 2018

Dementia NICE Guidelines Update. Key points for primary care - NICE guideline (June 2018 update ) 26 September 2018 Dementia NICE Guidelines Update Key points for primary care - NICE guideline (June 2018 update ) 26 September 2018 How NICE guidelines are reviewed Multidisciplinary guideline committee established Review

More information

Assessment and management of behavioral and psychological symptoms of dementia

Assessment and management of behavioral and psychological symptoms of dementia Assessment and management of behavioral and psychological symptoms of dementia Helen C Kales, 1 2 3 Laura N Gitlin, 4 5 6 Constantine G Lyketsos 7 1 Section of Geriatric Psychiatry, Department of Psychiatry,

More information

BEHAVIOURAL AND PSYCHOLOGICAL SYMPTOMS IN DEMENTIA

BEHAVIOURAL AND PSYCHOLOGICAL SYMPTOMS IN DEMENTIA BEHAVIOURAL AND PSYCHOLOGICAL SYMPTOMS IN DEMENTIA Unmet needs What might be your behavioural response to this experience? Content Definition What are BPSD? Prevalence How common are they? Aetiological

More information

Revised criteria for the clinical diagnosis of dementia with Lewy. Dementia with Lewy bodies. (Dementia with Lewy Bodies)

Revised criteria for the clinical diagnosis of dementia with Lewy. Dementia with Lewy bodies. (Dementia with Lewy Bodies) Dementia with Lewy bodies First described: Okazaki H, 1961, Diffuse intracytoplasmic ganglionic inclusions (Lewy type) associated with progressive dementia and quadriparesis in flexion. J Neuropathol Exp

More information

Parkinson s disease stakeholder workshop notes

Parkinson s disease stakeholder workshop notes Parkinson s disease stakeholder workshop notes Discussion on the scope relates to version 5.3 which was circulated at the stakeholder workshop. Group 1 o What aspects of the previous guideline would you

More information

SCIENTIFIC DISCUSSION

SCIENTIFIC DISCUSSION London, 2 March 2006 Product name: Prometax Procedure number: EMEA/H/C/255/II/33 SCIENTIFIC DISCUSSION 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 86

More information

Brain imaging for the diagnosis of people with suspected dementia

Brain imaging for the diagnosis of people with suspected dementia Why do we undertake brain imaging in dementia? Brain imaging for the diagnosis of people with suspected dementia Not just because guidelines tell us to! Exclude other causes for dementia Help confirm diagnosis

More information

Interface Prescribing Subgroup DRUGS FOR DEMENTIA: INFORMATION FOR PRIMARY CARE

Interface Prescribing Subgroup DRUGS FOR DEMENTIA: INFORMATION FOR PRIMARY CARE Cholinesterase inhibitors and Memantine are now classified as green (following specialist initiation) drugs by the Greater Manchester Medicines Management Group. Who will diagnose and decide who is suitable

More information

Current Treatments for Dementia and Future Prospects. James Warner St Charles Hospital, London

Current Treatments for Dementia and Future Prospects. James Warner St Charles Hospital, London Current Treatments for Dementia and Future Prospects James Warner St Charles Hospital, London Dementia Cognitive Non-cognitive (BPSD) Memory orientation language other cognitive abilities praxis planning

More information

Recommendations For the Use of Donepezil

Recommendations For the Use of Donepezil Recommendations For the Use of Donepezil The trial of donepezil in patients with mild to moderate dementia due to probable AD was one recommendation made by the Canadian Consensus Conference on Dementia.

More information

Dementia ALI ABBAS ASGHAR-ALI, MD STAFF PSYCHIATRIST MICHAEL E. DEBAKEY VA MEDICAL CENTER ASSOCIATE PROFESSOR BAYLOR COLLEGE OF MEDICINE

Dementia ALI ABBAS ASGHAR-ALI, MD STAFF PSYCHIATRIST MICHAEL E. DEBAKEY VA MEDICAL CENTER ASSOCIATE PROFESSOR BAYLOR COLLEGE OF MEDICINE Dementia ALI ABBAS ASGHAR-ALI, MD STAFF PSYCHIATRIST MICHAEL E. DEBAKEY VA MEDICAL CENTER ASSOCIATE PROFESSOR BAYLOR COLLEGE OF MEDICINE Objectives At the conclusion of the session, participants will be

More information

Rational Medication Use in Dementia

Rational Medication Use in Dementia Rational Medication Use in Dementia Stephen Thielke sthielke@u.washington.edu (206) 764 2815 I have no conflicts of interest to report. I am an employee of the federal government. The opinions in this

More information

Neurocognitive Disorders Research to Emerging Therapies

Neurocognitive Disorders Research to Emerging Therapies Neurocognitive Disorders Research to Emerging Therapies Edward Huey, MD Assistant Professor of Psychiatry and Neurology The Taub Institute for Research on Alzheimer s Disease and the Aging Brain Columbia

More information

SYNOPSIS (FOR NATIONAL AUTHORITY USE ONLY) INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER

SYNOPSIS (FOR NATIONAL AUTHORITY USE ONLY) INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER SYNOPSIS Protocol No.: RIS-USA-63 Psychosis in Alzheimer s disease (PAD) analysis Title of Study: A randomized, double-blind, placebo controlled study of risperidone for treatment of behavioral disturbances

More information

Title of Study: Evaluation of Efficacy and Safety of Galantamine in Patients With Dementia of Alzheimer's Type Who Failed to Benefit From Donepezil

Title of Study: Evaluation of Efficacy and Safety of Galantamine in Patients With Dementia of Alzheimer's Type Who Failed to Benefit From Donepezil SYNOPSIS Name of Sponsor/Company Name of Finished Product REMINYL Name of Active Ingredient(s) Galantamine hydrobromide Issue Date: 18 October 2013 Protocol No.: Title of Study: Evaluation of Efficacy

More information